Influenza virus resisting nasal mucosa absorbent and preparation thereof

An anti-influenza virus, nasal mucosa technology, applied in the direction of antiviral agent, aerosol delivery, etc., can solve problems such as easy oxidative polymerization

Inactive Publication Date: 2008-07-09
谭文界
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] However, the pyrogallol structure of EGCG and ECG makes them easily oxidized and polymerized in solution, which is a problem for formulation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Influenza virus resisting nasal mucosa absorbent and preparation thereof
  • Influenza virus resisting nasal mucosa absorbent and preparation thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] 1. The main physical and chemical properties of EGCG and ECG: easy to oxidative polymerization reaction, solid state is more stable than solution, good water solubility, easy to be affected by light, heat, oxygen, acid and alkali.

[0021] Preparation: Take EGCG and add PEG in proportion to mix. Granulate, dry the granules in vacuum at low temperature, and press into tablets. Film-coated, vacuum-packed in aluminum foil, each tablet contains 70mg of EGCG, and add 18g of sodium acetate and 9.8ml of glacial acetic acid to dissolve and dilute with distilled water To 1000ml. That is the spray solvent of PH4.5. Packed into 10ml / bottle, put the tablet into the spray bottle to dissolve the spray when using.

[0022] 2. Experimental research on anti-influenza virus of epigallocatechin-3-0-gallate (EGCG) and epicatechin-3-0-gallate (ECG) in vitro.

[0023] 1. Experimental materials

[0024] 1.1 Cells Dog kidney passage cells (MDCK) were provided by the Wuhan Center for Disease C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses anti-influenza virus nasal mucosa absorbent and a preparation method thereof, in the invention, epi-gallocatechin-3-O-gallate (EGCG) or epicatechin-3-O-gallate (ECG) solid preparation is used as efficacy component and acetic acid-sodium acetate buffer solution is used as solvent. The EGCG or the ECG solid preparation is dissolved into the acetic acid-sodium acetate buffer solution. The concentration of the nasal mucosa absorbent is 6 to 7mg / ml. The EGCG and ECG are considered as anti-influenza virus efficacy component to be made into solid and liquid to be packed separately and are mixed and dissolved for using, which effectively solves the problem that the EGCG and the ECG are not stable in the solution with short shelf life and prolongs the usage period of the EGCG and the ECG preparation. The nasal mucosa absorbent of the present invention acts on the influenza virus directly with fast absorption speed and can effectively inhibit the influenza virus.

Description

field of invention [0001] The invention relates to a pharmaceutical preparation and a preparation method, in particular to the field of preventing and treating cold and influenza. Background of the invention [0002] Colds and influenza are common and frequently-occurring diseases, all caused by viruses. [0003] Utilizing pharmaceutical preparations to effectively inhibit influenza virus is a research topic in the current medical field. Studies have confirmed that: EGCG and ECG have a significant inhibitory effect on influenza virus entering cells, with obvious dose-effect relationship, low toxicity and wide safety range. [0004] Related literature, patent application 01106982.1 "an anti-leukemia drug" discloses an anti-leukemia drug with epigallocatechin gallate as the main raw material. It is used for the treatment of acute promyelocytic leukemia, chronic myeloid leukemia, and retinoic acid-resistant promyelocytic leukemia. It is a leukemia gene regulator, which can si...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/12A61K31/353A61P31/16
Inventor 谭文界左小章祝汪洋谭静玲
Owner 谭文界
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap